Shiseki Masayuki, Masuda Akihiro, Watanabe Norimichi, Fujii Masami, Kimura Tomofumi, Yoshinaga Kentaro, Mori Naoki, Teramura Masanao, Motoji Toshiko
Department of Hematology;
Hematol Rep. 2011 Aug 31;3(2):e10. doi: 10.4081/hr.2011.e10. Epub 2011 Aug 30.
Waldenström's macroglobulinemia (WM)/ lymphoplasmacytic lymphoma (LPL) is an indolent mature B-cell neoplasm. In rare cases of WM/LPL, diffuse large B-cell lymphoma (DLBCL) develops as a result of histologic transformation. In this report, we present a case of DLBCL developing in a patient with WM/LPL. Combination chemotherapy for DLBCL was effective and complete remission was eventually achieved. We attempted to determine the clonal relatedness between WM/LPL and DLBCL in the patient by analyzing complementarity-determining region 3 (CDR3) in the immunoglobulin heavy chain gene. A common CDR3 sequence was found in tumor cells of DLBCL and those of WM/LPL, indicating that tumor cells of DLBCL are clonally identical to those of WM/LPL. Therefore, in the present case, DLBCL is developed from WM/LPL cells by clonal evolution.
华氏巨球蛋白血症(WM)/淋巴浆细胞淋巴瘤(LPL)是一种惰性成熟B细胞肿瘤。在罕见的WM/LPL病例中,会因组织学转化而发展为弥漫性大B细胞淋巴瘤(DLBCL)。在本报告中,我们呈现了1例在WM/LPL患者中发生DLBCL的病例。针对DLBCL的联合化疗有效,最终实现了完全缓解。我们试图通过分析免疫球蛋白重链基因中的互补决定区3(CDR3)来确定该患者中WM/LPL与DLBCL之间的克隆相关性。在DLBCL的肿瘤细胞和WM/LPL的肿瘤细胞中发现了共同的CDR3序列,这表明DLBCL的肿瘤细胞与WM/LPL的肿瘤细胞克隆相同。因此,在本病例中,DLBCL是由WM/LPL细胞通过克隆进化发展而来的。